Castration-Resistant Prostate Cancer (CRPC) Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Castration-Resistant Prostate Cancer (CRPC) Treatment Market Forecast 2024-2028

The Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market size is estimated to grow by USD 5.98 billion at a CAGR (Compound Annual Growth Rate) of 8.83% between 2023 and 2028. The escalating prevalence of cancer worldwide, claiming over ten million lives annually, propels this market forward. Prostate cancer, causing over a million deaths yearly, predominantly afflicts men over 50, a demographic set to double by 2050. Consequently, prostate cancer rates are poised for a significant surge. Simultaneously, the global market for castration-resistant prostate cancer (CRPC) treatment is expected to witness substantial growth.

However, despite regulatory approval, CRPC drugs carry side effects, potentially impeding market growth. The ailment is addressed through targeted therapies and radiotherapy, while symptoms like blood in the urine and shortness of breath indicate advanced prostate cancer. Comprehensive market analysis offers insights into CRPC incidence and treatment strategies, shaping market trends.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation by Distribution Channel, Therapy, and Geography Analysis

Distribution Channel Analysis

The hospital pharmacies segment is estimated to witness significant growth during the forecast period. The hospital pharmacies segment is a distinct category of pharmacies that operate within the premises of a healthcare facility. In addition, the fundamental objective of hospital pharmacies is overseeing the proper subscription and intake of medications by patients within hospitals and other healthcare facilities.

Get a glance at the market contribution of various segments Download PDF Sample

The hospital pharmacies segment was the largest segment and was valued at USD 6.35 billion in 2018. Moreover, this encompasses various tasks, such as choosing appropriate medications, prescribing them, procuring them, ensuring their timely delivery, administering them, and conducting thorough reviews to enhance patient outcomes. In addition, it is of utmost significance to uphold the principles of patient safety by meticulously adhering to the correct patient dosage, administration route, timing, drug, information, and documentation for every medication that is prescribed. Furthermore, as these pharmacies are located inside the hospital campus, the demand for CRPC drugs is higher in these stores.  Hence, the demand for CRPC medications in hospital pharmacies will drive the market growth and trends during the forecast period.

Therapy Analysis

The hormonal therapy segment can be referred to as a medical intervention that halts the production or delivery of testosterone to the cancer cells in the prostate, effectively impeding their growth. In addition, the growth of cancer cells in the prostate is heavily dependent on the amount of testosterone, and hormonal therapy disrupts this process by inducing cell death or slowing down the growth of cancerous cells. Moreover, hormonal therapy for prostate cancer may encompass the administration of medication or the potential removal of the testicles surgically.  Furthermore, a few doctors advise the patient to stay on hormonal therapy as it prevents a rise in the natural testosterone levels and will also affect testosterone-lowering therapy which could cause cancer to grow alarmingly Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The market in North America has been growing steadily, fuelled by the rise in the prevalence of prostate cancer cases. In addition, the presence of highly advanced healthcare infrastructure is fueling the growth of the regional market. Moreover, the significant rise in the number of prostate cancer patients in the region offers opportunities to companies operating in the regional market. For instance, according to the American Cancer Society, approximately 268,490 new cases of prostate cancer were reported in the US in 2022, resulting in 34,500 deaths. Hence, such factors are driving the market growth in North America during the forecast period.

Buy Full Report Now

Market Dynamics and Customer Landscape 

Driven by the escalating prevalence of cancer worldwide, claiming over ten million lives annually, prostate cancer stands out as a significant ailment, causing over a million deaths yearly. While its exact cause remains elusive, factors like age significantly elevate the risk, especially among men over 50. With this demographic projected to double by 2050, prostate cancer rates are expected to surge. Correspondingly, the castration-resistant prostate cancer (CRPC) treatment market anticipates substantial growth.

Currently, four approved drugs target CRPC, including abiraterone acetate, which inhibits androgen biosynthesis, reducing specific hormone levels. Despite regulatory approval, these medications carry side effects, from joint pain to life-threatening irregular heartbeats, potentially impeding market growth. Additionally, addressing CRPC involves targeted therapies, radiotherapy, and antineoplastic drugs like non-steroidal antiandrogens and corticosteroids, typically administered orally or via injection. Symptoms such as blood in the urine and shortness of breath indicate advanced prostate cancer. Comprehensive market analysis and reports offer insights into CRPC incidence and treatment strategies, pivotal in navigating this complex landscape.

 Key Market Drivers

This market is driven by the escalating prevalence of cancer worldwide, claiming over ten million lives annually. Among the most common types, prostate cancer stands out, causing over a million deaths yearly. While the exact cause remains elusive, factors like age elevate the risk. Prostate cancer predominantly afflicts men over 50, a demographic set to double by 2050, according to the World Health Organization. Consequently, prostate cancer rates are poised for a significant surge in the forecast period. Concurrently, the global market for castration-resistant prostate cancer (CRPC) treatment is expected to witness substantial growth.

Currently, four approved drugs target CRPC, including abiraterone acetate, which inhibits androgen biosynthesis, reducing specific hormone levels. Despite regulatory approval, these medications carry side effects, ranging from joint pain to life-threatening complications like irregular heartbeats. Such health risks associated with CRPC drugs may impede market growth in the forecast period. The ailment is further addressed through targeted therapies and radiotherapy, while antineoplastic drugs like non-steroidal antiandrogens and corticosteroids are also administered, typically through the oral or injectable route. Symptoms like blood in the urine and shortness of breath are indicative of advanced prostate cancer. Comprehensive market analysis and reports provide insights into CRPC incidence and treatment strategies.

Significant Market Trends

A key factor shaping the castration-resistant prostate market growth is the evolving CRPC treatment options. Currently, there is no conventional therapy for CRPC patients who experience elevated prostate-specific antigen (PSA) levels while undergoing androgen deprivation therapy without any visible metastases. In addition, a reduced time to first metastasis and death has been linked to a short PSA doubling time in men with progressive non-metastatic CRPC.

Moreover, many companies are developing alpha particle-emitting radioactive therapeutic agents for the treatment of CRPC. For example, Bayer AG has successfully created a radioactive therapeutic agent that emits alpha particles. In addition, this treatment has gained approval in over 50 countries across the world for treating CRPC effectively and alleviating symptoms caused by bone metastases. Furthermore, Bayer AG is expanding its range of treatments for prostate cancer by introducing an androgen receptor inhibitor (ARi), which is specifically designed for non-metastatic castration-resistant prostate cancer (nmCRPC). Hence, such factors are positively impacting the market. This is one of the major market trends.

Major Market Challenges

Health complications related to CRPC drugs are one of the key challenges hindering market growth. Currently, there are four approved treatment drugs available for patients with CRPC, namely docetaxel plus prednisone; cabazitaxel; abiraterone acetate; and sipuleucel-T. Abiraterone, in conjunction with prednisone, is prescribed to treat a specific form that has metastasized to other areas of the body. In addition, abiraterone belongs to a group of medications known as androgen biosynthesis inhibitors.

Moreover, its mechanism of action involves reducing the levels of certain hormones in the body. Even though the medications are approved by regulatory bodies, they have some side effects. In addition, the side effects of Abiraterone include joint swelling or pain, groin pain, hot flushes (a sudden wave of mild or intense body heat), diarrhea, constipation, heartburn, cough, difficulty falling asleep or staying asleep, sore throat, stuffy or runny nose, and others. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market during the forecast period.

Buy Now Full Report

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market growth and forecasting report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Active Biotech AB: The company offers CRPC treatment such as Tasquinimod TASQ, which is in trial phase III, for men with metastatic castrate-resistant prostate cancer, in partnership with Ipsen.

• Allarity Therapeutics Inc.
• Amgen Inc.
• Amneal Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Bayer AG
• BeiGene Ltd.
• Daiichi Sankyo Co. Ltd.
• Dr Reddys Laboratories Ltd.
• Everest Pharmaceuticals Ltd.
• F. Hoffmann La Roche Ltd.
• Johnson and Johnson
• Medias Klinikum GmbH and Co. KG
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Robotic Prostate Centre Cambridge
• Sanofi SA
• The Focal Therapy Clinic
• Ono Pharmaceutical Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Our market trends and analysis report includes data that is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Key Customer Landscape

The market research and growth report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth analysis report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Customer Landscape

Market Analyst Overview

The Castration-Resistant Prostate Cancer (CRPC) Treatment Market is witnessing significant advancements in various areas, including combination therapies and hormone therapy, particularly androgen deprivation therapy (ADT). While surgical castration and medical castration have been conventional methods, personalized medicine is emerging as a promising approach.

Research and development efforts are driving innovations in the technological integration of diagnostic tools such as genomic testing and liquid biopsies. These tools, along with imaging technologies, play a crucial role in understanding the mechanisms of CRPC and assessing the efficacy of treatments.

Across the Europe market, government initiatives are fueling clinical trials to explore second-line hormone therapy, immunotherapy, and radiopharmaceutical therapy. Drugs like enzalutamide are gaining prominence, supported by regulatory agencies like the Food and Drug Administration.

As awareness and diagnosis rates rise, there's a growing demand for new treatments beyond conventional medications. Emerging therapies like Pluvicto (lutetium Lu 177 vipivotide tetraxetan) show promise in addressing symptoms such as difficulty urinating, pain while passing urine, and weight loss among the geriatric population. These advancements signify a positive shift in healthcare expenditure towards combating CRPC and improving patient outcomes.

Segment Overview

The market forecasting report covers market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Distribution Channel Outlook
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Therapy Outlook
  • Hormonal therapy
  • Chemotherapy
  • Others
• Geography Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Australia
    • Argentina
    • Brazil

Castration-Resistant Prostate Cancer (CRPC) Treatment Market Scope
Market Report Coverage	Details
Page number	160
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 8.83%
Market Growth 2024-2028	USD 5.98 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	5.7
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 47%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	Active Biotech AB, Allarity Therapeutics Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Everest Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, Medias Klinikum GmbH and Co. KG, Merck KGaA, Novartis AG, Pfizer Inc., Robotic Prostate Centre Cambridge, Sanofi SA, The Focal Therapy Clinic, and Ono Pharmaceutical Co. Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2024 and 2028
• Precise estimation of the market size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch